课题基金 / 基金详情

Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism

Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism
AD 综合疗法:γ 分泌酶调节和 CRFR1 拮抗相结合
批准号:
8771201
负责人:
Robert A Rissman
金额:
$19.38万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2016-04-30

项目摘要

项目成果

Robert A Rissman的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is defined neuropathologically by extracellular plaques composed of ¿-amyloid (A¿) and intracellular tangles consisting of hyperphosphorylated forms of the microtubule-associated protein tau. A¿ accumulation and hyperphosphorylation of tau are recognized as key events leading to full blown AD neuropathology. Here we propose to use a unique set of small molecule drugs (gamma-secretase modulators and CRFR1 antagonists) to further explore novel AD therapeutics. This application will focus on the efficacy of drugs aimed at both A¿- and tau-related pathologies in AD transgenic mice. Our overarching hypothesis is combination therapy aimed to disrupt production of both A¿42 and hyperphosphorylated tau will be an efficacious treatment approach for prodromal or early AD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HABS-HD - Core D - Omics Core
Novel Systemic Delivery of Peptide-Mediated Anti-Sense Oligonucleotides for Dementia with Lewy Bodies
Novel Antagonists of the N-terminal Domain of the CRF Receptor Type 1 for Alzheimer's Disease
Neuropathology Core